Apotal acquisition lifts Zur Rose in Germany

Apotal acquisition lifts Zur Rose in Germany

23 October 2020 - Deborah Wilkes

Zur Rose Group – the e-commerce pharmacy that owns DocMorris – said its share of the online pharmacy market in Germany had risen to 43% following the recent acquisition of Apotal.

The Swiss company said Apotal, which was acquired in August 2020 (click here to read the News story), had added seven percentage points to its market share.

In the third quarter of 2020, sales at Zur Rose’s German business, including Apotal and Medpex, increased by 18.1% in local currencies to CHF275 million (USD304 million). The rise as reported was 14.6%.

The German business accounted for 63.2% of Zur Rose’s total sales in the quarter, which reached CHF435 million. This represented a rise of 15.3% in local currencies and 12.9% as reported compared to the same period a year earlier.

Zur Rose said the number of active customers at the group had increased by 600,000 during the quarter to 9.8 million.

Performance in Switzerland

Sales at Zur Rose's Switzerland business rose by 7.3% to CHF146 million, accounting for 33.6% of the group’s total.

Sales by the Rest of Europe business, which covers Zur Rose’s marketplaces in Spain and France, increased by 59.7% in local currency terms to CHF15.6 million. Sales as reported were up by 54.7%.

Click tags below for more information on topics:

Zur Rose

Back to Industry News

Share this page: